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Summary
Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucos-
amine sulfate in two recent 3-year, randomised, placebo-controlled clinical trials, in which conventional standing antero-posterior full
extension knee radiographs were used for the measurement of joint space narrowing, and in which pain relief might have improved knee full
extension.
Design: Patients completing the 3-year treatment course were selected based on a WOMAC pain decrease at least equal to the mean
improvement in the glucosamine sulfate arms in either of the original studies, irrespective of treatment with glucosamine sulfate or placebo
(drug responders or placebo responders). In a second approach, 3-year completers were selected if their baseline standing knee pain (item
#5 of the WOMAC pain scale) was ‘severe’ or ‘extreme’ and improved by any degree at the end of the trials. In both cases, changes in
minimum joint space width were compared between treatment groups.
Results: Global knee pain was mild-to-moderate in the two study populations and in all patient subsets identified. There were obviously more
pain improvers in the glucosamine sulfate subsets (N76 in the two studies combined) than in the placebo subsets (N57), but WOMAC
pain scores improved to the same extent, which was as large as over 50% relative to baseline. Nevertheless, the placebo subsets in both
studies underwent an evident mean (SD) joint space narrowing, which in the pooled analysis of both studies was −0.22 (0.80) mm, and was
not observed with glucosamine sulfate: +0.15 (0.60) mm (P0.003 vs placebo). Similar results were found in the smaller subsets with
≥ severe baseline standing knee pain that improved after 3 years, with a joint space narrowing nevertheless of −0.28 (0.76) mm with placebo
(N26), not observed with glucosamine sulfate: +0.21 (0.68) mm (N31; P0.014 vs placebo).
Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials using
conventional standing antero-posterior radiographs, possibly due to the mild-to-moderate patient characteristics.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Drugs for the treatment of osteoarthritis are classified as
symptom-modifying or structure-modifying drugs, depend-
ing on their ability to control the symptoms of the disease or
the progression of joint structure changes, according to the
recommendations laid down by scientific and regulatory
authorities1–4. Much emphasis has been placed on joint
structure modification as the most important determinant
of disease progression. Therefore, structure-modifying
drugs have become synonymous with disease-modifying
drugs, although the latter should probably be able to
modify the progression of both symptoms and structural
damages.
Assessment of changes in joint space width by plain
radiography is the best available surrogate marker of
articular cartilage loss, currently the preferred target for
joint structure changes in osteoarthritis. Radiographic joint
space narrowing is therefore the primary outcome measure
for the efficacy of possible disease-modifying drugs, as
recommended by scientific organisations1,2 and acknowl-
edged by regulatory agencies such as the European
Medicine Evaluation Agency (EMEA)3 and the United
States Food and Drug Administration (FDA)4. At the level of
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the knee joint, and in particular of the tibiofemoral compart-
ment, the gold standard radiographic protocol is the stand-
ing (weight-bearing) antero-posterior fully extended knee
view, as reported in the Osteoarthritis Research Society
guidelines published in 19965. Nevertheless, commend-
able research has been conducted since then which later
identified potential problems of this gold standard tech-
nique, mainly concerning the standardisation of the knee
radioanatomic position6,7 with consequences principally on
the precision of the measurement8 and the possibility of
underestimating the rate of joint space narrowing. While
none of the recent semi-flexed views proposed to over-
come some of the theoretical limitations of conventional
standing antero-posterior films has been sufficiently vali-
dated in longitudinal studies so far9, several epidemiologic
studies and prospective clinical trials have been in the
meantime reported, which substantially increased our
knowledge about the progression of osteoarthritis in gen-
eral and of joint structure changes in particular10–13, and on
the effects of drugs. Obviously, these studies used the gold
standard technique available at the time of study design,
performance and analysis. In particular, two prospective,
3-year, randomised, placebo-controlled clinical trials have
been very recently reported by our respective groups,
which indicated, for the first time with any therapeutic
intervention, the effect of a drug, namely glucosamine
sulfate, as a disease-modifying agent in osteoarthritis14,15.
Designed in 1994 and independently conducted and re-
ported thereafter, these two studies obviously adopted the
conventional standing antero-posterior radiographic view.
Indeed, the two studies independently observed that glu-
cosamine sulfate was able to significantly prevent the joint
space narrowing occurring in the patients receiving placebo
throughout the 3 years of treatment. Interestingly, this
finding has been criticised for the potential systematic error
that might have been introduced by the other major effect
observed, i.e., the significant improvement of symptoms in
the glucosamine sulfate-treated patients compared with
placebo-treated patients. This symptom-modifying effect
has been indicated as a major clinical finding16 and would
fully characterise glucosamine sulfate as a disease-
modifying drug in osteoarthritis. On the other hand, it has
been hypothesised that the concomitant reduction in joint
pain seen in the glucosamine sulfate arm, relative to
placebo, altered the positioning of the knee (in particular
favouring a better knee full extension), resulting in a
change in joint space width that might have confounded the
estimate of joint space narrowing and exaggerated the
differences between treatment groups9. These criticisms
have been fuelled by the recent observation that major
relief in extremely severe knee pain in flaring knees actually
biased the evaluation of joint space width with conventional
standing antero-posterior films17. Although this latter con-
dition does not reflect the conditions of patients in our trials
and although our study reports had specifically excluded
such a confounder14,15, these criticisms continued and
failed9,18 to take into account the second glucosamine
sulfate report that in the meantime has been published
in extenso and with additional information in this
regard15.
The present investigation has been therefore undertaken
with the aim of re-analysing our data in light of the recent
criticisms and to finally assess whether improvement in
knee pain was a confounder in the assessment of joint
space width in our study populations and whether it biased
the structure-modifying effect reported for glucosamine
sulfate.
Methods
PATIENT SELECTION AND METHODS OF THE ORIGINAL STUDIES
Patient entry criteria and the general methodology of the
trials are described in details in the two original study
publications14,15. In brief, outpatients of both genders were
selected on the basis of a diagnosis of primary knee
osteoarthritis according to the clinical and radiological
criteria of the American College of Rheumatology19. Radio-
graphic changes were present at least in the medial
tibiofemoral compartment.
Both trials were conducted according to a randomised,
placebo-controlled, double-blind design, with patients
assigned to receive a 3-year continuous treatment with
either placebo, or crystalline glucosamine sulfate (Dona,
Viartril-S, Xicil, or other trademarks by the Rotta Research/
Rottapharm Group, Monza, Italy) at the oral dose of
1500 mg once-a-day as a soluble powder formulation.
Radiographs were obtained according to the gold stan-
dard technique available at the time of study design, i.e.,
with the standing (weight-bearing) antero-posterior fully
extended knee view. The radiographic protocols were re-
markably similar, as described in the two original re-
ports14,15. In particular, the focus to film distance was fixed
as well as all other radiographic parameters and settings
(i.e., kilovolts, milliamperes and milliseconds). In addition,
the posterior aspect of the knee was in contact with the
X-ray cassette in order to avoid variation in the distance
between the knee and the cassette throughout the study.
Finally, fluoroscopy was used to direct the X-ray beam to
the centre of the joint space, to control for joint rotation and
thus to maintain the same degree of alignment with the
tibial plateau in subsequent radiographs. In both trials,
patient repositioning was guided by the baseline film and
aided by foot maps in the Reginster’s study and by placing
the feet together in the Pavelka’s study.
For the purpose of the present subset analysis, the
efficacy evaluation methods that were common to the two
studies were used to report the data. In particular, for the
structure-modifying effect, joint space width of the medial
tibiofemoral compartment was assessed at the joint nar-
rowest point by the visual technique of ‘chondrometry’20
with the aid of a 10× magnifying lens graduated in 0.1 mm.
For the symptom-modifying effect, the WOMAC index
(global and for the pain, function and stiffness subscales in
the original study reports)21 was used throughout the
studies. The visual analogue scale (VAS) version of the
index (VA-3.0) was used in one trial14 and the Likert scale
version (LK-3.0) in the other15.
AIMS AND METHODS OF THE PRESENT RE-ANALYSIS
The aim of the present subset analysis was to assess
whether improvement in knee pain in the glucosamine
sulfate arms of the studies resulted in an artifactual in-
crease in joint space width, possibly by improving the ability
of knee full extension. Two different approaches were
followed to assess this hypothesis.
In the first approach, patients completing the 3-year
treatment course and the study evaluations were selected
on the basis of a major global knee pain improvement at
the end of the trial relative to baseline values, regardless of
treatment with glucosamine sulfate or placebo (i.e., both
drug and placebo responders). Since the symptomatic
improvement obtained with glucosamine sulfate in the two
original studies was postulated to be responsible for the
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possible bias in the radiographic joint structure evalu-
ation9,17,18, the cut-off of pain improvement for defining
such responders was set to a decrease in the WOMAC
pain subscale equal to the mean intention-to-treat improve-
ment observed in the glucosamine sulfate groups in the two
original reports14,15. Changes in joint space width in this
subset of pain improvers were then analysed to see if there
was still any difference between the glucosamine sulfate
and placebo groups (see Statistical Analysis section): the
working hypothesis was that if major pain relief leads to
artifactual increase in joint space width, no joint space
narrowing should be observed in either of these patient
subgroups, irrespective of treatment with glucosamine
sulfate or placebo.
In the second approach, 3-year completers in the two
original studies were presently selected if they had a higher
chance not to be able to fully extend their knee at baseline
due to severe pain while standing, and if this pain had
improved by any degree at the end of the trials. For this
purpose we used the ‘flaring knee’ definition described by
Mazzuca et al.17 and patients were thus selected if they
had reported at baseline that standing knee pain (i.e., item
#5 of the WOMAC pain subscale) was ‘severe’ or ‘extreme’,
i.e., score 3 or 4 on the 0–4 WOMAC Likert scale adopted
in the study by Pavelka et al.15 or, by analogy, >60 mm out
of 100 mm in the WOMAC VAS scale used by Reginster
et al.14. In addition, for patients to be selected for this
subset analysis, this standing pain should have improved
by at least 1 point on the Likert scale, or >20 mm on the
VAS scale, again regardless of treatment with glucosamine
sulfate or placebo. Changes in joint space width were then
compared between treatment groups also in this case (see
Statistical Analysis section).
STATISTICAL ANALYSIS
Results for the patient subsets reported here are pre-
sented separately for each of the two original studies and,
as the primary analysis, in a single data pool.
Changes after 3 years in the WOMAC pain scores were
calculated for the patient subsets described in the Methods
section. Due to the different scale version adopted in the
two original studies (VAS and Likert scale version of
the index), in order to allow a direct comparison between
the studies and, above all, to pool the data, the WOMAC
pain results are reported as percentage changes relative to
baseline. Comparisons between treatment groups were
performed by analysis of variance.
The primary outcome measure for structure modification
in the two original studies, that was used as such in this
re-analysis, was the change in joint space width after 3
years in the narrowest medial tibiofemoral compartment at
baseline (signal joint). Primary comparisons between treat-
ment groups in the different pain-improver subsets were
performed by analysis of variance. However, since this
patient selection was based on a post-randomisation oc-
currence (pain improvement), it may not be protected by
the randomisation and may need to be adjusted for relevant
baseline confounders, e.g., baseline joint space width in
this case. Therefore, a secondary analysis was performed
covariating on baseline joint space width values.
Results
A total of 212 and 202 patients (414 overall) were
enrolled in the studies by Reginster et al.14 and Pavelka
et al.15, respectively. Patients’ characteristics have been
described in details in the two study reports14,15.
Table I reports the baseline mean WOMAC pain scores
and joint space widths in the full study populations of
the two original studies and in the pain-improver subsets
defined according to the first approach elaborated in the
present study. As clearly stated in the two original re-
ports14,15, patients participating in the two trials had knee
osteoarthritis of mild-to-moderate severity, both from the
point of view of symptoms as witnessed by the WOMAC
pain scores and in terms of baseline joint space width that
Table I
Mean baseline WOMAC pain scores and joint space width in the full study populations and in the identified subsets of knee pain improvers
Placebo Glucosamine sulfate
WOMAC pain*
Full study population
Reginster et al. (N=106, 106) 172 (105) mm 194 (102) mm
Pavelka et al. (N=101, 101) 6.3 (3.1) points 6.6 (3.5) points
Pain-improver subset
Reginster et al. (N=30, 35) 236 (96) mm 228 (94) mm
Pavelka et al. (N=27, 41) 8.0 (3.0) points 7.3 (2.8) points
Joint space width†
Full study population
Reginster et al. (N=106, 106) 3.95 (1.24) mm 3.82 (1.32) mm
Pavelka et al. (N=101, 101) 3.63 (1.57) mm 3.89 (1.48) mm
Pain-improver subset
Reginster et al. (N=30, 35) 4.21 (0.87) mm 3.65 (1.05) mm
Pavelka et al. (N=27, 41) 3.64 (1.62) mm 4.10 (1.43) mm
Both studies pooled (N=57, 76) 3.94 (1.30) mm 3.90 (1.28) mm
Data are reported as mean (SD). Data of the full study populations of Reginster et al. and Pavelka et al. are derived from the two study
reports (references 14 and 15). N represents the number of patients in the placebo and glucosamine sulfate groups, respectively.
*Values correspond to the sum of scores for all five items in the WOMAC pain subscale and are reported in millimetre for the study by
Reginster et al., in which the 0–100 mm VAS version was used to score each item, and in points for the study by Pavelka et al., in which the
0–4 Likert version was used to score each item.
†Joint space width measured in millimetre at the joint narrowest point.
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was between 3.5 and 4.0 mm in both studies and without
differences between treatment groups (Table I).
As reported in the Methods section, the pain-improver
patients selected for the first approach re-analysis were
those who had an improvement in the WOMAC pain scores
at least equal to the average decrease observed in the
glucosamine sulfate-treated groups of the two original
studies, corresponding to 35.8 mm in the sum of VAS
scores in the study by Reginster et al.14 and 2.0 points in
the sum of Likert scores in the study by Pavelka et al.15.
Baseline average WOMAC pain scores and joint space
width of these patient subsets are also reported in Table I.
There were obviously more patients in the glucosamine
sulfate subsets (drug responders) than in the placebo
subsets (placebo responders), but the baseline WOMAC
pain scores were similar between treatments and only
slightly higher compared to the two original full study
populations. Joint space widths in the pain-improver sub-
sets (Table I) were also similar to those of the respective full
study populations, with only a small increase in the placebo
subset of the study by Reginster et al. and, vice versa, in
the glucosamine sulfate subset of the study by Pavelka
et al.. On the other hand, when the data from the two study
subsets were pooled, the average minimum joint space
width was around 3.9 mm for both placebo and glucos-
amine sulfate subsets (Table I).
By definition, the pain-improver subsets identified in the
current re-analysis had a major decrease in WOMAC pain
scores at the end of the 3 years of the studies, correspond-
ing to around 50% of their baseline values (Fig. 1). In
addition, Fig. 1 clearly shows that although the number of
responder patients was obviously larger in the glucosamine
sulfate groups, there were no significant quantitative differ-
ences between treatment groups in terms of average knee
pain relief. Despite the similar magnitude of the major pain
relief in both treatment group subsets, Fig. 2 shows that
placebo-treated patients underwent an evident joint space
narrowing that was not observed in the patient subsets that
had received glucosamine sulfate for the 3 years of the
trials. This pattern was identical in both the studies by
Reginster et al. in which, notwithstanding the small number
of patients that could be included in this subanalysis, the
difference between treatment groups was statistically sig-
nificant (P0.019) (Fig. 2, panel B), as well as in the study
by Pavelka et al., in which the difference was at the limits of
statistical significance (P0.06) (Fig. 2, panel C) in the
primary analysis. When the results from the two studies
are pooled and thus a larger patient sample is obtained
(N57 with placebo and N76 with glucosamine sulfate;
Fig. 2, panel A), the opposite pattern between treatment
groups is highly statistically significant, with a mean (SD)
joint space narrowing of −0.22 (0.80) mm with placebo,
Fig. 1. WOMAC pain mean (SE) decrease in global knee pain improvers. Panel A reports the data pooled from both studies, while panels
B and C show the data from the single studies of Reginster et al. and Pavelka et al., respectively. N represents the number of patients who
qualified for the analysis in the placebo and glucosamine sulfate groups.
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which was not observed with glucosamine sulfate: 0.15
(0.60) mm (P0.003). The degree of statistical signifi-
cance in the difference between groups did not change
when the data were analysed covariating on baseline
joint space width values (P0.002 for the pooled data set,
P0.048 for the study by Reginster et al.), and statistical
significance is also reached when the study by Pavelka
et al. is considered alone (P0.046).
Remarkably, the mean degree of joint space narrowing
attained with placebo in these pain-responder subsets (Fig.
2, panels B and C) after 3 years was −0.30 mm for the
patients derived from the study by Reginster et al. and
−0.14 for those from Pavelka et al., i.e., in the same range
of changes observed in the two original studies, similar to
the changes observed in the glucosamine sulfate subsets.
By analogy, this means that the remaining patients, i.e.,
those who did not show any improvement in their knee pain
or those who did not reach the stipulated cut-off for pain
relief, behaved in the same way. Joint space narrowing
after treatment with placebo in this latter patient subset was
only marginally and not significantly larger than in defined
pain-responders as shown in Fig. 2 and was −0.42
(0.94) mm when pooled between the two studies. Con-
versely, glucosamine sulfate-treated patients in this subset
did not experience any joint space narrowing: 0.09
(0.86) mm (P0.003 vs placebo).
When patients from the two original studies were se-
lected according to the second approach described in the
Methods section, i.e., considering only those with severe or
extreme standing knee pain at baseline and improving by
any degree after 3 years, the sample size was further
reduced in these subpopulations that consisted of only
12–15% of the total number of patients randomised in each
treatment group (N10 and 17 in the study by Reginster
et al. and N16 and 14 in the study by Pavelka et al., in the
placebo and glucosamine sulfate groups, respectively).
Most of the patients in these subpopulations belonged to
the previously described pain-responder subsets, with the
exception of 10 patients overall who did not qualify as
global WOMAC pain ‘improvers’, despite a 3-year decrease
in their severe standing knee pain. Baseline global
WOMAC pain scores were logically slightly higher than
those in the overall study populations or in the previous
responder subsets as shown in Table I, but were still in the
mild-to-moderate mean (SD) range: 275 (86) and 268 (106)
mm in the Reginster’s study (VAS scores), and 9.6 (2.5) and
8.8 (2.0) points in the Pavelka’s study (Likert scores), for
placebo and glucosamine sulfate, respectively. Conversely,
Fig. 2. Mean (SE) change in joint space width after 3 years in the global knee pain-improver subsets described in Fig. 1. Panel A reports the
data pooled from both studies, while panels B and C show the data from the single studies of Reginster et al. and Pavelka et al., respectively.
N represents the number of patients who qualified for the analysis in the placebo and glucosamine sulfate groups. The P values presented
here were obtained by analysis of variance. Analysis of covariance adjusting for baseline joint space width produced P values of 0.002, 0.048
and 0.046 for panels A, B and C, respectively.
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minimum joint space width baseline values in the pooled
subset populations did not differ from those previously
described: 3.9 (1.3) and 3.5 (1.4) mm for placebo (N26)
and glucosamine sulfate (N31), respectively. Also in this
case, as depicted in Fig. 3, despite the severe or extreme
standing knee pain at enrolment that improved throughout
the studies, placebo-treated patients experienced a joint
space narrowing that was not seen in those treated with
glucosamine sulfate (Fig. 3, panels B and C). Although the
differences between treatments were not statistically sig-
nificant in the primary analysis for the two single studies
because of the very limited number of patients in these
subsets, P was 0.014 when the results from both studies
were pooled (Fig. 3, panel A), with a joint space narrowing
of −0.28 (0.76) mm with placebo and no loss with glucos-
amine sulfate: 0.21 (0.68) mm. The P value was 0.017 for
the pooled data set in the secondary analysis performed
covariating on baseline joint space width, which reached
statistical significance (P0.041) in the study by Reginster
et al. but not for the study by Pavelka et al. (P0.14). There
were too few completers in this subset who did not report
improvement in standing knee pain and only one in whom it
worsened, to allow for a meaningful analysis of these
further patients.
Discussion
In the present re-analysis of the data from two random-
ised, placebo-controlled, double-blind, 3-year trials show-
ing disease modification with glucosamine sulfate14,15, we
have demonstrated that the structure-modifying effects of
the drug, observed by conventional standing antero-
posterior knee radiographs, were not biased by the con-
comitant pain relief induced by glucosamine sulfate relative
to placebo. This finding is contrary to what was postulated
by recent reviews9,18 that did not consider the details of the
two long-term trial results and suspected that pain relief
might have selectively improved knee extension with a
consequent alteration in radioanatomic positioning, poten-
tially obscuring actual joint space narrowing in subjects
receiving glucosamine sulfate. Indeed, our data clearly
show that patients experiencing major knee pain relief
irrespective of treatment (i.e., drug responders or placebo
responders), nevertheless, undergo joint space narrowing
when they have received placebo, but not when they have
been treated with glucosamine sulfate over the 3 years of
the trials.
In our first methodological approach, patients have been
selected according to the minimum degree of pain relief
Fig. 3. Mean (SE) change in joint space width after 3 years in the subset of patients with standing knee pain (item #5 in WOMAC pain scale)
at least severe at baseline and improving by any degree after 3 years. Panel A reports the data pooled from both studies, while panels B and
C show the data from the single studies of Reginster et al. and Pavelka et al., respectively. N represents the number of patients who qualified
for the analysis in the placebo and glucosamine sulfate groups, respectively. The P values presented here were obtained by analysis of
variance. Analysis of covariance adjusting for baseline joint space width produced P values of 0.017, 0.041 and 0.14 for panels A, B and C,
respectively.
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suspected of being a confounding factor, i.e., with a cut-off
equivalent to the mean improvement on the WOMAC
pain subscale in the glucosamine sulfate groups of both
studies14,15. Patients in this subset had an average relief of
global knee pain that was as large as 50% of their baseline
value with either placebo or, obviously in a higher pro-
portion of cases, glucosamine sulfate, but nevertheless
they suffered a joint space narrowing with placebo that was
significant compared with those who received the drug. To
exclude that this result was due to a wrong patient selection
for this subset analysis and that a bias might have been
operative only in those patients likely to face the worst
difficulty in fully extending their knees at enrolment, a
second approach was also explored. In this second analy-
sis, only patients with standing knee pain (item #5 of the
WOMAC pain subscale) rated ‘severe’ or ‘extreme’ at
baseline and improving to any degree after 3 years were
selected, but the results were identical to those of the first
approach.
Conventional standing antero-posterior radiographs
have been recently criticised due to the possibility of
changes in knee flexion and knee positioning between
X-rays. Indeed, apparent joint space width in the extended
knee may be highly sensitive to small changes in flexion
due to more rapid loss of cartilage in the more posterior
portions of the femoral cartilage, and the joint riding up on
the femoral condyles and the meniscus during full exten-
sion7. In addition, this conventional technique may be
subject to longitudinal changes in medial tibial plateau
alignment8. Changes in alignment may indeed derive from
failure to reproduce the degree of knee extension achieved
at baseline, so that changes in the knee extension/flexion
pattern may alter the distance between the centre of the
joint and the X-ray cassette. This possibility is real if
adequate technical measures to avoid changes in align-
ment are not taken and especially for particular patient
populations in which knee full extension may not be
achieved at baseline. Conversely, several measures had
been adopted in the studies by Reginster et al.14 and
Pavelka et al.15 to avoid this possibility and included the
use of fluoroscopy that minimised the effect of medial tibial
plateau alignment and assured reproducibility of the radio-
graphs serially taken during the two trials. Fluoroscopy and
uniform positioning guidelines have been shown indeed to
afford superior reproducibility of joint space width measure-
ment in conventional standing antero-posterior radio-
graphs22. In addition, the patients enrolled in the long-term
glucosamine sulfate trials had baseline disease in general,
and global knee pain levels in particular, of mild-to-
moderate severity and thus not preventing knee full exten-
sion on the entry radiograph. The results of the present
re-analysis are therefore not in contrast with those of
Mazzuca et al.17, in whose report, on the other hand, the
studies by Reginster et al. and Pavelka et al. were criti-
cised. In facts, Mazzuca et al.17 showed that in patients
with extreme severity standing and global knee pain, joint
space width artifactually increased with pain relief. Al-
though the authors did not assess any problems with knee
extension/flexion, their finding is plausible. However, such
severe patients are inadequate for long-term, placebo-
controlled disease-modifying drug trials and, definitely, they
did not enter the Reginster’s or the Pavelka’s trial14,15. In
fact, even when in the present study we selected patients
with extreme standing knee pain at enrolment according
to Mazzuca’s definition of ‘flaring’ knee17, their global
WOMAC pain score was in any case only slightly higher
than that exhibited by the overall population in the two
glucosamine sulfate studies14,15 and always in the mild-to-
moderate severity range. This was therefore far from the
extreme global knee pain severity that can be deducted
from the small sample in the study by Mazzuca et al.17. A
bias in patient repositioning may therefore be operative
only in patients with extreme severity global knee pain
scores and not in those with mild-to-moderate severity
enrolled in our long-term trials who rather seem to be more
similar to those indicated by Mazzuca et al. as ‘non-
flaring’17.
The changes in joint space width we observed in the
subsets of patients with major pain relief are similar to
those reported for the global patient populations of the two
original studies14,15, as well as to those of the opposite
subset of patients in whom pain was not relieved to the
same extent or it worsened. It is confirmed therefore that
the correlation between radiographic joint space narrowing
and symptoms is at best poor. On the other hand, the
slightly more (although not significantly) pronounced joint
space narrowing observed in placebo-treated patients who
could not be classified as ‘pain improvers’, is compatible
with a global disease progression, involving both symptoms
and joint space narrowing to a slightly larger extent than in
placebo-treated patients in whom pain improved during the
study. This observation is in agreement with the modest,
though significant, correlation described by Bruyere et al.23
between knee pain and joint space narrowing in the
placebo-treated patients of the Reginster’s trial14. In these
patients, the best predictor of changes in joint space width
was its baseline value, with patients with wider joint space
width suffering the most dramatic narrowing after 3 years24.
Conversely, our present results show that glucosamine
sulfate protective effects on joint structure changes are
independent of the drug symptomatic effect. In the present
study, we have therefore excluded that changes in joint
pain were a source of error in patient repositioning: this has
been indicated as the only potential bias that could have
affected the interpretation of the glucosamine sulfate
structure-modifying effect9,17,18.
The results of other studies in which patients different
from those in the glucosamine sulfate trials may have been
enrolled, namely patients in whom extreme knee pain might
have prevented knee full extension, should be evaluated
with care as already suggested17, since this may be a
potential confounding factor with standing antero-posterior
radiographs.
In conclusion, major relief in mild-to-moderate global
knee pain is not a confounder in the evaluation of joint
space narrowing on standing antero-posterior knee radio-
graphs taken in full extension. Doubts had been postulated
in this regard9,17,18 and relative to the validity of the
structure-modifying effects of glucosamine sulfate in two
recent independent long-term trials14,15. Conversely, these
structure-modification results are valid and were not biased
by the concomitant symptom modification observed with
the drug, nor by any other limitations in the conventional
radiographic technique adopted. Glucosamine sulfate
is therefore suggested as the first disease-modifying
drug in osteoarthritis, displaying both a symptom- and a
structure-modifying effect over a long-term treatment
course.
While acknowledging the inherent limitations of conven-
tional standing antero-posterior radiographic protocols that
may suggest adoption of more efficient techniques in the
future, care should be taken in verifying whether real biases
occurred in previous studies using such gold standard,
prior to raising unjustified warnings.
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